Evolution Research Group | Behavioral Research Specialists, LLC

Research site

(Unclaimed)

Location

230 N. Maryland Avenue, Suite 207, Glendale, California, United States of America

Site insights

Top conditions

Top treatments

Rapastinel

Cariprazine

Aticaprant

MK-8189

Troriluzole

Lithium

Vilazodone

Seltorexant

Eszopiclone

AVP-786

Parent organization

This site is a part of Evolution Research Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 68 total trials

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA2)

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling

Major Depressive Disorder

Drug: Placebo

Drug: Azetukalner

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (EMBRACE)

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in pat...

Enrolling

Depression in Adults

Depression Disorders

Drug: CYB003

Behavioral: Psychological Support

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmuco...

Enrolling

Treatment Resistant Depression

Drug: VLS-01-BU Placebo

Drug: VLS-01-203 BU

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:1. Is SN...

Enrolling

Moderate Alzheimer Disease

Biological: SNK01

Other: Placebo

Open-Label Extension Protocol to SNK01-AD01 Study

Enrolling

Alzheimer Disease

Biological: SNK01

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling

Depressive Disorder, Major

Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Drug: Placebo